Mark Cuban’s Generic Drug Company Has Disruptive Potential In Niche Markets

How disruptive Cuban’s company will be depends on the types of drugs it will sell. It’s unclear at this time whether Cuban’s company will be in direct competition with the established players for a wide range of products, or whether it will focus on niche markets, such as the one for albendazole.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive